Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. - Wikidata - awgldk - TriplyDB

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

http://www.wikidata.org/entity/Q39955421

about

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review Dengue Fever: Causes, Complications, and Vaccine Strategies Understanding the dengue viruses and progress towards their control Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques Serotype-Specific Structural Differences in the Protease-Cofactor Complexes of the Dengue Virus Family Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4 30-4995 in Healthy Adult Volunteers Dengue research opportunities in the Americas Issues related to recent dengue vaccine development.Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines.Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control.Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.Bioinformatics in new generation flavivirus vaccines.Safety and immunogenicity of a rederived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial.Dengue in Thailand and Cambodia: an assessment of the degree of underrecognized disease burden based on reported cases.Induction of neutralization antibodies in mice by Dengue-2 envelope DNA vaccines.A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.National dengue surveillance in Cambodia 1980-2008: epidemiological and virological trends and the impact of vector control Dengue vaccines: state of the art.Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever.Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.Dengue vaccines: recent developments, ongoing challenges and current candidates.Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis Health economics of dengue: a systematic literature review and expert panel's assessment.Forecasting dengue vaccine demand in disease endemic and non-endemic countries.Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine Next-generation dengue vaccines: novel strategies currently under development.Distinct Humoral and Cellular Immunity Induced by Alternating Prime-boost Vaccination Using Plasmid DNA and Live Viral Vector Vaccines Expressing the E Protein of Dengue Virus Type 2 Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study Sculpting humoral immunity through dengue vaccination to enhance protective immunity A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.Domain III of the envelope protein as a dengue vaccine target.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies.

P2860

Q26314710-EC9312E8-64FF-4E5A-9944-5F6D4982C789 Q26700078-CFFF8A6B-9E61-4D2D-9122-D65758B3D496 Q26700082-7A9246A7-BA91-4598-B481-293F371FD75F Q27011587-585DBA01-F2C6-4103-868A-8FC6AC5A97BA Q27334248-BD4D9AEB-365E-4A98-B682-6FC4BDD11BBF Q27490960-F8498071-E871-45EA-82D2-FC35508ECFBC Q27490989-A715B7F1-6CE2-43AE-935A-E17643FB8BC7 Q28656204-D274107E-5189-4CA9-876E-53FD75BBBA6C Q30395396-B73D86A3-F086-410A-8CFD-E2D38334F3DC Q33699057-0222E41D-ECC8-482C-9B9C-626623FC0ED7 Q33709817-6913C53F-8F5C-478B-AE73-CA13451AA494 Q33743890-8BAA7318-7026-4DEC-A816-731DE732AFE7 Q33839001-E2E60953-6ACA-4FA6-ADD9-9FB9B74AB30A Q33841045-1D515E57-8FCF-4FB9-9CEB-766A2904E421 Q33863578-5018EA1D-E545-4F0E-8511-0ED0F9C5B395 Q33961878-083C7A27-B1D7-4C91-AD28-E69AC4034A28 Q33988937-A9EC66F1-C321-4309-8B4B-F83B785AD06D Q34092769-2CBFB424-0509-4F8D-84C2-D431B4F577BE Q34109652-80B160F5-2A82-4D1F-815E-2538EE7E1A6C Q34202440-ECF3FAB8-CE00-45DC-8A04-629DB6DA5E1C Q34306877-67F267BC-2B88-48E7-B2C7-752724110834 Q34367194-841132A4-867D-4864-8B37-321C707D39DA Q34423720-3046B364-3989-4023-AE02-8E81FEF9D918 Q34592267-39EEC887-CE11-45E8-AA0C-BC352068B0E6 Q34663963-D94FA0C5-5164-4630-A7BE-EC32C6C17C7B Q34663993-D2A66A08-997B-46AE-92D6-F12F32EDFCFF Q35131443-5BD07A2E-288F-4E91-B9E6-17C68B025906 Q35206695-A1C8D63D-1A1E-4C4E-B3FD-9676AC928D93 Q35491639-4138AB0C-5486-4106-AAE6-AAC17A03B8A1 Q35624552-1FD0104C-78E9-4387-BF89-CA4D822E97C0 Q36024479-E93E3720-1397-49F8-B56C-750EF3F005CF Q36288109-00B7D7FB-5630-4859-A614-9BA5D4CEE5E9 Q36382589-87F4D353-9AE9-4108-9CD7-59EBB28EE455 Q36523070-011129D0-9C6F-4916-B7DD-DA82FA1669A2 Q36607295-25042553-DC9A-4B31-BB4B-C4687DDCFE05 Q36849774-57D542E3-E467-42DC-93D3-11D83FBBE861 Q37682895-0FEA6031-BEFA-46BE-82FD-3BF6E86CD210 Q37694855-541C0F4A-DC4A-4D1D-BF88-82B9F29D3EBF Q37706823-05741064-825B-4D1C-9549-FEA7D82F4206 Q37812291-3BCCB3DD-FE5A-4037-8D61-EB9CBE74307A

P2860

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.

http://www.wikidata.org/entity/Q39955421

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@en

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@nl

type

label

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@en

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@nl

prefLabel

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@en

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@nl

P1433

Q39955421-E271A1BB-2CEB-41ED-822D-261D8B1FEC18

P1476

Q39955421-4064854D-E716-49D6-9829-2ABE5979F8DC

P2093

Q39955421-0EDA59DF-E3BF-47A0-BDBA-556EC389FF92

Q39955421-5A58A990-19D6-45B1-A067-062E35057AD3

Q39955421-6F6071D5-8F3B-48F5-99DA-8A32BC5DB16C

Q39955421-76584F9D-06FF-480E-8256-D27F8103700D

Q39955421-9E0AAB4C-8F96-472E-843A-3A1AC0B9F66D

Q39955421-9F3FF339-92B2-445D-9D2A-E339B55C65C6

Q39955421-A35641C2-E16B-450F-8186-4CA2D5D78094

Q39955421-DE7A0BF1-B68E-4CDA-BC8C-397AF3081387

Q39955421-F36BD45C-CE12-44A6-A667-BF216768175B

Q39955421-F49FECF4-21E8-4A48-8E97-3C59B0AE49D2

P304

Q39955421-4BAE59EF-5F1A-44AC-9DA4-61A9291673F8

P31

Q39955421-6652041B-3A0D-4C0A-A12E-89B146D26E9E

P356

Q39955421-129274EF-D944-4231-A1BB-D2A2011D3DAE

P433

Q39955421-F20DEFE0-EA9A-43BC-990A-02F6ABD7E42C

P478

Q39955421-4AC755EB-B991-43B5-9D1E-4A81025B6E7D

P50

Q39955421-FB1C8955-F590-4DA5-B9FE-29A3509E1C0C

P5008

Q39955421-85E237FF-3B90-4576-A121-B308EECDD2AF

P577

Q39955421-3DA77695-BADF-4E73-88B2-54ADF607EDFC

P5875

Q39955421-6ACBAA2B-2066-4AA0-8707-5DC120C92EAF

P698

Q39955421-98F38182-9362-4F9A-9702-67A249EFC977

P921

Q39955421-104F986A-5152-4582-A7CD-73DE27F8B271

Q39955421-957982EC-0F7B-4F7A-8992-CB7CE0CB4977

Q39955421-990DA6EF-AEB1-47FA-8F56-5399CC13FA87

P356

P1433

P1476

Phase 2 clinical trial of thre ...... ne in flavivirus-naïve adults.

@en

P2093

David W Vaughn

http://www.w3.org/2001/XMLSchema#string

Dennis Cunningham

http://www.w3.org/2001/XMLSchema#string

J Robert Putnak

http://www.w3.org/2001/XMLSchema#string

Judith Perry

http://www.w3.org/2001/XMLSchema#string

Kenneth H Eckels

http://www.w3.org/2001/XMLSchema#string

Niranjan Kanesa-Thasan

http://www.w3.org/2001/XMLSchema#string

Robert Edelman

http://www.w3.org/2001/XMLSchema#string

Stephen J Thomas

http://www.w3.org/2001/XMLSchema#string

Steven S Wasserman

http://www.w3.org/2001/XMLSchema#string

Wellington Sun

http://www.w3.org/2001/XMLSchema#string

P304

33-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/HV.5.1.6348

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2009-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23140537

http://www.w3.org/2001/XMLSchema#string

P698

18670195

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

phase II clinical trial